Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-28, Stock:ABBV, The news for the past five days is as follows:
2018-09-21: NEWS1: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS2: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS3: AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know.NEWS4: Hagens Berman Alerts Investors in AbbVie Inc. (ABBV) to the Firm's Investigation of Possible Humira-Related Health Insurance Fraud and Disclosure Violations.NEWS5: CLASS ACTION UPDATE for AMPE, COCP, ABBV and SKX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS6: INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS7: Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status.NEWS8: Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status.NEWS9: AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation of AbbVie Inc. - ABBV.NEWS10: CRON Stock Is a Long-term Play With Near-Term Challenges.NEWS11: EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against AbbVie Inc. – ABBV.NEWS12: Drugmakers' Free Services Trigger Anti-Kickback Probe.NEWS13: AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy.NEWS14: How Do Drugs Compete Against Each Other?.NEWS15: How Do Drugs Compete Against Each Other?.NEWS16: How Do Drugs Compete Against Each Other?.
2018-09-24: NEWS1: Hagens Berman Alerts Investors in AbbVie Inc. (NYSE: ABBV) to the November 20, 2018 Securities Class Action Lead Plaintiff Deadline.NEWS2: CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline.NEWS3: ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm.NEWS4: CRON Stock Is a Long-term Play With Near-Term Challenges.NEWS5: CRON Stock Is a Long-term Play With Near-Term Challenges.NEWS6: SPYG, BA, ABBV, ADBE: ETF Inflow Alert.NEWS7: SPYG, BA, ABBV, ADBE: ETF Inflow Alert.NEWS8: AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU.NEWS9: AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU.NEWS10: IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS11: AbbVie/Roche&apos;s Leukemia Drugs Combo Gets CHMP Backing in EU.NEWS12: AbbVie Class Action: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc - ABBV.
2018-09-25: NEWS1: Gilead (GILD) to Launch Generics for Leading HCV Treatments.NEWS2: Gilead (GILD) to Launch Generics for Leading HCV Treatments.NEWS3: Exploring Idexx Laboratories’ Operational Performance.NEWS4: How Idexx Laboratories Is Positioned in 2018.NEWS5: ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm.NEWS6: Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against AbbVie Inc. (ABBV).
2018-09-26: NEWS1: Gilead Is Undercutting Its Own Drugs: Here's Why.NEWS2: Gilead Is Undercutting Its Own Drugs: Here's Why.NEWS3: Gilead Is Undercutting Its Own Drugs: Here&apos;s Why.NEWS4: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2018 – ABBV.NEWS5: Analyzing Eli Lilly’s Valuation Trends.NEWS6: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV).NEWS7: What Idexx Laboratories’ Valuation Trend Indicates.
2018-09-27: NEWS1: IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018.NEWS3: SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV.NEWS4: Pfizer’s Earnings Quality and Dividend Performance.NEWS5: Peek Under The Hood: EQWL Has 10% Upside.NEWS6: Peek Under The Hood: EQWL Has 10% Upside.NEWS7: Gilead Sciences' Latest Tactic? Go Generic.NEWS8: Gilead Sciences' Latest Tactic? Go Generic.NEWS9: Gilead Sciences&apos; Latest Tactic? Go Generic.

Answer: Rise